Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

VCYT Veracyte Inc

Price (delayed)

$30.76

Market cap

$2.41B

P/E Ratio

71.53

Dividend/share

N/A

EPS

$0.43

Enterprise value

$2.27B

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other ...

Highlights
Veracyte's net income has surged by 148% YoY and by 37% QoQ
The EPS has surged by 146% year-on-year and by 34% since the previous quarter

Key stats

What are the main financial stats of VCYT
Market
Shares outstanding
78.31M
Market cap
$2.41B
Enterprise value
$2.27B
Valuations
Price to earnings (P/E)
71.53
Price to book (P/B)
2.01
Price to sales (P/S)
5.18
EV/EBIT
64.76
EV/EBITDA
36.04
EV/Sales
4.9
Earnings
Revenue
$463.39M
Gross profit
$315.19M
Operating income
$23.7M
Net income
$33.05M
EBIT
$35.08M
EBITDA
$63.03M
Free cash flow
$78.45M
Per share
EPS
$0.43
EPS diluted
$0.41
Free cash flow per share
$1.01
Book value per share
$15.33
Revenue per share
$5.94
TBVPS
$5.92
Balance sheet
Total assets
$1.32B
Total liabilities
$120.48M
Debt
$50.5M
Equity
$1.19B
Working capital
$308.03M
Liquidity
Debt to equity
0.04
Current ratio
5.1
Quick ratio
4.56
Net debt/EBITDA
-2.18
Margins
EBITDA margin
13.6%
Gross margin
68%
Net margin
7.1%
Operating margin
5.1%
Efficiency
Return on assets
2.6%
Return on equity
2.8%
Return on invested capital
23.7%
Return on capital employed
2.8%
Return on sales
7.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
3.53%
1 week
-1.79%
1 month
-3.27%
1 year
43.94%
YTD
-22.32%
QTD
3.74%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$463.39M
Gross profit
$315.19M
Operating income
$23.7M
Net income
$33.05M
Gross margin
68%
Net margin
7.1%
Veracyte's net income has surged by 148% YoY and by 37% QoQ
The net margin has soared by 139% YoY and by 31% from the previous quarter
The operating income has soared by 130% YoY and by 47% from the previous quarter
The operating margin has soared by 124% YoY and by 42% from the previous quarter

Price vs fundamentals

How does VCYT's price correlate with its fundamentals

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
P/E
71.53
P/B
2.01
P/S
5.18
EV/EBIT
64.76
EV/EBITDA
36.04
EV/Sales
4.9
The EPS has surged by 146% year-on-year and by 34% since the previous quarter
The P/B is 20% below the 5-year quarterly average of 2.5 and 4.3% below the last 4 quarters average of 2.1
The equity has grown by 7% YoY
The P/S is 47% below the 5-year quarterly average of 9.8 and 6% below the last 4 quarters average of 5.5
Veracyte's revenue has increased by 23% YoY and by 4% QoQ

Efficiency

How efficient is Veracyte business performance
The company's return on equity has surged by 144% YoY and by 33% QoQ
The ROA has soared by 144% YoY and by 37% from the previous quarter
The return on sales has surged by 140% year-on-year and by 31% since the previous quarter
VCYT's return on invested capital has surged by 122% year-on-year but it is down by 3.7% since the previous quarter

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The total liabilities has grown by 48% YoY but it has contracted by 2.9% from the previous quarter
Veracyte's total assets has increased by 10% YoY
The debt is 96% less than the equity
The equity has grown by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.